RMC No. 62-2025: Updated VAT-Exempt Medicines List for Cancer, Diabetes, Hypertension, High Cholesterol, Mental Illnesses, and Tuberculosis

RMC No. 62-2025 updates VAT-exempt medicines for key diseases, requiring pharmacies and healthcare sellers to verify FDA publication and product tax codes. Pharmacies, hospitals, clinics, distributors, importers, and VAT-registered sellers of covered medicines must immediately check the latest FDA-published VAT-exempt medicines list before issuing invoices, pricing products, or claiming VAT treatment. RMC No. 62-2025 confirms […]

RMC No. 59-2025: VAT-Exempt Medicines List Updated for Cancer, Diabetes, Hypertension, Kidney Disease, and Tuberculosis Products

RMC No. 59-2025 updates VAT-exempt medicines for key diseases, with effectivity tied to FDA Advisory issuance and proper product validation. Businesses dealing in medicines for cancer, diabetes, hypertension, kidney disease, and tuberculosis must immediately check whether their covered products are included in the updated VAT-exempt medicines list endorsed by the Food and Drug Administration. RMC […]

RMC No. 25-2025: FDA Updates to VAT-Exempt Medicines for Diabetes, Hypertension, High Cholesterol, and Mental Illness

RMC No. 25-2025 confirms FDA updates to VAT-exempt medicines for diabetes, hypertension, high cholesterol, and mental illness under TRAIN and CREATE. Businesses selling, purchasing, distributing, or accounting for medicines covered by the FDA’s updated VAT-exempt list must immediately review their product master files, invoicing settings, and VAT treatment because the VAT exemption takes effect upon […]

RMC No. 131-2024: Updated VAT-Exempt Medicine List for Cancer, Diabetes, and Mental Illness Products

RMC No. 131-2024 updates the VAT-exempt medicine list for cancer, diabetes, and mental illness products, with effectivity tied to FDA publication. Businesses selling, dispensing, importing, distributing, or accounting for qualified medicines must immediately check the latest FDA-published list of VAT-exempt medicines because the VAT exemption under the CREATE Act takes effect based on the FDA’s […]

RMC No. 34-2024: FDA Updates to VAT-Exempt Medicines for Cancer, Hypertension, and Mental Illness Under TRAIN and CREATE

RMC No. 34-2024 confirms FDA updates to VAT-exempt medicines for cancer, hypertension, and mental illness, with effect from FDA publication. Businesses selling medicines for cancer, hypertension, and mental illness must immediately check the latest Food and Drug Administration updates to the VAT-exempt product list because VAT exemption takes effect on the date the FDA publishes […]

RMC No. 17-2024: Updated VAT-Exempt Medicines List for Cancer, Diabetes, Hypertension, Kidney Disease, Mental Illness, and Tuberculosis

RMC No. 17-2024 updates VAT-exempt medicines for key diseases, including inclusions and a hypertension medicine deletion tied to FDA publication. Pharmaceutical companies, drugstores, hospitals, clinics, and VAT-registered sellers of medicines must immediately verify whether the medicines they sell are affected by the latest FDA-endorsed updates to the VAT-exempt medicines list. RMC No. 17-2024 publishes the […]

RMC No. 42-2023: VAT-Exempt Medicines List Updated for FDA-Endorsed Products Under TRAIN and CREATE

RMC No. 42-2023 confirms FDA-endorsed updates to VAT-exempt medicines and applies exemption from FDA publication of the updated list. Pharmacies, hospitals, clinics, drug distributors, importers, and accounting teams dealing with medicines for cancer, diabetes, kidney disease, mental illness, tuberculosis, high cholesterol, and hypertension should immediately verify whether their products are covered by the FDA-endorsed updates […]

RMC No. 19-2023: VAT Exemption Updates for FDA-Endorsed Medicines and Medical Devices Under TRAIN and CREATE

RMC No. 19-2023 confirms FDA-endorsed VAT-exempt medicine and medical device updates, with CREATE Act exemption effective from FDA publication date. Businesses selling, purchasing, importing, prescribing, distributing, or accounting for VAT-exempt medicines and medical devices must verify whether their products are included in the Food and Drug Administration’s updated VAT-exempt list, because VAT exemption under the […]

RMC No. 116-2022: Updated VAT-Exempt Medicines List for Hypertension, Diabetes, Kidney Disease, Mental Illness, Cancer, and Deleted COVID-19 Medicines

RMC No. 116-2022 updates the VAT-exempt medicines list under CREATE, adding certain chronic disease medicines and deleting some COVID-19 medicines. Pharmacies, hospitals, clinics, distributors, importers, and accounting teams handling medicines must immediately check whether their products remain VAT-exempt, newly qualify for VAT exemption, or have been removed from the VAT-exempt list. RMC No. 116-2022 confirms […]

RMC No. 110-2022: VAT Exemption Updates for Certain Cancer and COVID-19 Medicines Under the CREATE Act

RMC No. 110-2022 updates VAT-exempt medicines under CREATE, covering certain cancer and COVID-19 medicines effective upon FDA publication. Businesses selling, purchasing, importing, prescribing, or accounting for medicines used in cancer and COVID-19 treatment must verify whether the specific medicines they handle are now included in the updated List of VAT-Exempt Medicines. RMC No. 110-2022 matters […]